COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX:CLN) today announced the completion of its Phase I dose escalation study, using ThermoDox®, to treat non-resectable liver cancer. The study which was conducted under a Cooperative Research and Development Agreement (CRADA) was performed at the National Cancer Institute (NCI) of the National Institutes of Health, under the leadership of Dr. Steven K. Libutti, Senior Investigator, Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, NCI and Dr. Bradford J. Wood, Chief, Interventional Radiology Research at the National Institutes of Health Clinical Center and at Queen Mary Hospital in Hong Kong under the leadership of Dr. Ronnie T. P. Poon, MD, Professor of Surgery, Faculty of Medicine at Queen Mary Hospital, University of Hong Kong.
